Pay in 4 interest-free payments of $6.29 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
The discrepancies may reflect black market sourcing, where some products marketed as retatrutide may not be retatrutide at all
Triple-hormone-receptor agonist Retatrutide for obesity: Phase 2 trial (48-week study, up to 24% weight loss) American Diabetes Association (2023) ADA Press Release: Novel agent Retatrutide results in substantial weight reduction (83rd Scientific Sessions, Phase 2 data) ADA Meeting News (2023) Phase 2 trial results: benefits of Retatrutide in obesity, type 2 diabetes, NASH (83rd ADA Scientific Sessions coverage) ClinicalTrials.gov Study of Retatrutide (LY3437943) in adults with obesity (NCT04881760
TRIUMPH-5: type 2 diabetes, active-comparator design
"Airline lobbying for a relaxation of draconian rules for London-Auckland travellers"
US$ 25.62
US$ 22.01
US$ 28.15
US$ 24.26
US$ 29.67
